How often do inhibitors develop in people taking Coageight for hemophilia A?
Part of Blood & lymphatic, Genetic & congenital clinical trials.
This study looks at how many people with hemophilia A develop inhibitors (antibodies that stop factor VIII from working) after taking Coageight, a factor VIII medicine. It will help doctors understand how safe this treatment is for the long term.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Male, age 2 or older
- Diagnosed with hemophilia A
- Have received at least 50 total exposure days to any factor VIII product in your lifetime
- Have used the factor VIII medicine Coageight at least 10 times in the past year
- Do not have any other bleeding or clotting disorder (unless treated with immune tolerance therapy)
- Do not have hepatitis B or C
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is looking at the safety and effectiveness of a factor VIII medicine called octocog alfa (used to treat bleeding) in men with severe hemophilia A in India. It will track how well the medicine works and any side effects during routine care.
This study looks at why the body sometimes stops responding to factor VIII treatment in hemophilia A. It aims to find patterns that help doctors predict and manage this, so they can keep the treatment working well.
This trial studies a treatment approach for people with hemophilia A who develop antibodies (inhibitors) that block clotting factor FVIII. It may help those whose usual FVIII therapy is not working because of these inhibitors.
This study checks joint health and bleeding risk in people with severe hemophilia A who are taking newer factor VIII treatments or emicizumab. It uses ultrasound and blood tests to see how well these therapies protect joints.
This study looks at how well a medicine called damoctocog alfa pegol (Jivi) works to prevent bleeding in children with hemophilia A. It will follow children who are already using this medicine or starting it, to see how effective it is in real life.
This study tests a new medicine called NXT007 for people with hemophilia A. It compares NXT007 to standard factor VIII treatment to see if it works better at preventing bleeding episodes.
Hear when a new Hemophilia A trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.